Operator

Ladies and gentlemen, welcome to the Immunovia Q2 Interim Report 2026 Conference Call. I’m Lorenzo, the Chorus Call operator. [Operator Instructions].

The conference is being recorded. The conference must not be recorded for publication or broadcast. At this time, it’s my pleasure to hand over to Jeff Borcherding, CEO. Please go ahead, sir.

Jeff Borcherding
Global Chief Executive Officer & President

Thank you very much, and thank you to all of you for joining us today for the review of Immunovia’s second quarter of 2026. As we will share, we have achieved important milestones in the commercialization of PancreaSure, and we are transitioning to the second phase of the PancreaSure test launch.

We’re also excited about the progress that we continue to make in the pursuit of Medicare coverage, and we’ll share updates on our efforts there. I’m also pleased with our business development progress as we have ongoing conversations with potential partners. As you can imagine, I won’t be able to share a lot about the specifics of those opportunities, but wanted you to know that we are focused on business development and are pursuing a number of paths there.

So for today’s call, we will focus initially on the commercial uptake and traction of the PancreaSure test. We’ll also talk a little bit about some of the drivers of growth in the second half of the year.

My colleague, Adam, will cover our Q2 financial results and our cash position. And then I will come back to discuss clinical studies that are in progress and our reimbursement efforts as well as those business development opportunities that I mentioned.